SCANCELL HOLDINGS PLC is pleased to announce that Phil L'Huillier, CEO and Sath Nirmalananthan, CFO will provide an Investor Update via Investor Meet Company on 24 Apr 2025, 14:30 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 23 Apr 2025, 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet SCANCELL HOLDINGS PLC via:
Investors who already follow SCANCELL HOLDINGS PLC on the Investor Meet Company platform will automatically be invited.
About Scancell
Scancell (LSE:SCLP) develops immunotherapies for a Cancer-free future by enhancing long-lasting tumour specific immunity. As a clinical stage biotechnology company with deep roots in cancer immunology and translational research, Scancell develops tumour targeted off-the-shelf vaccines, with highly favourable safety and durable systemic immune responses. Scancell's lead product, iSCIB1+, a DNA vaccine, is currently showing strong promise on top of checkpoint therapies in a multi-arm phase 2 study in first-line melanoma. The second vaccine Modi-1 is being investigated in a phase 2 study in a broad range of solid tumours. Scancell is also developing a pipeline of high affinity antibodies targeting tumour specific glycans using its proprietary platforms. Two of these antibodies are now being developed in major biopharma partnerships and a further two antibodies targeting lung and epithelial cancers, are actively being developed in-house.